These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 26289310

  • 1. Extracorporeal Elimination of Piperacillin/Tazobactam during Molecular Adsorbent Recirculating System Therapy.
    Personett HA, Larson SL, Frazee EN, Nyberg SL, El-Zoghby ZM.
    Pharmacotherapy; 2015 Aug; 35(8):e136-9. PubMed ID: 26289310
    [Abstract] [Full Text] [Related]

  • 2. Molecular Adsorbent Recirculating System (MARS(®)) removal of piperacillin/tazobactam in a patient with acetaminophen-induced acute liver failure.
    Ruggero MA, Argento AC, Heavner MS, Topal JE.
    Transpl Infect Dis; 2013 Apr; 15(2):214-8. PubMed ID: 23279615
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration.
    Varghese JM, Jarrett P, Boots RJ, Kirkpatrick CM, Lipman J, Roberts JA.
    Int J Antimicrob Agents; 2014 Apr; 43(4):343-8. PubMed ID: 24612982
    [Abstract] [Full Text] [Related]

  • 4. Molecular Adsorbent Recirculating System Therapy with Continuous Renal Replacement Therapy Enhanced Clearance of Piperacillin in a Pediatric Patient and Led to Failure to Attain Pharmacodynamic Targets.
    Tang Girdwood S, Arbough T, Dong M, Mizuno T, Tang P, Vinks AA, Kaplan J.
    Pharmacotherapy; 2020 Oct; 40(10):1061-1068. PubMed ID: 32916003
    [Abstract] [Full Text] [Related]

  • 5. Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients.
    Chung EK, Cheatham SC, Fleming MR, Healy DP, Shea KM, Kays MB.
    J Clin Pharmacol; 2015 Aug; 55(8):899-908. PubMed ID: 25823963
    [Abstract] [Full Text] [Related]

  • 6. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ, Shankar V, Schlichting C, Kuti JL.
    Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
    [Abstract] [Full Text] [Related]

  • 7. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
    Yost RJ, Cappelletty DM, RECEIPT Study group.
    Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
    [Abstract] [Full Text] [Related]

  • 8. Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.
    Lee GC, Liou H, Yee R, Quan CF, Neldner K.
    Clin Ther; 2012 Dec; 34(12):2297-300. PubMed ID: 23195962
    [Abstract] [Full Text] [Related]

  • 9. Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.
    Asín-Prieto E, Rodríguez-Gascón A, Trocóniz IF, Soraluce A, Maynar J, Sánchez-Izquierdo JÁ, Isla A.
    J Antimicrob Chemother; 2014 Jan; 69(1):180-9. PubMed ID: 23908259
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
    Awissi DK, Beauchamp A, Hébert E, Lavigne V, Munoz DL, Lebrun G, Savoie M, Fagnan M, Amyot J, Tétreault N, Robitaille R, Varin F, Lavallée C, Pichette V, Leblanc M.
    Pharmacotherapy; 2015 Jun; 35(6):600-7. PubMed ID: 26095008
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
    Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP.
    J Antimicrob Chemother; 2014 Jan; 69(1):176-9. PubMed ID: 23869050
    [Abstract] [Full Text] [Related]

  • 12. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients.
    Shea KM, Cheatham SC, Wack MF, Smith DW, Sowinski KM, Kays MB.
    Int J Antimicrob Agents; 2009 Nov; 34(5):429-33. PubMed ID: 19726163
    [Abstract] [Full Text] [Related]

  • 13. The effect of the molecular adsorbent recirculating system on moxifloxacin and meropenem plasma levels.
    Roth GA, Sipos W, Höferl M, Böhmdorfer M, Schmidt EM, Hetz H, Schebesta K, Klaus D, Motal M, Jäger W, Krenn CG.
    Acta Anaesthesiol Scand; 2013 Apr; 57(4):461-7. PubMed ID: 23237505
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients.
    Sturm AW, Allen N, Rafferty KD, Fish DN, Toschlog E, Newell M, Waibel B.
    Pharmacotherapy; 2014 Jan; 34(1):28-35. PubMed ID: 23864417
    [Abstract] [Full Text] [Related]

  • 15. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
    Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R, RENAL Replacement Therapy Study Investigators.
    Crit Care Med; 2012 May; 40(5):1523-8. PubMed ID: 22511133
    [Abstract] [Full Text] [Related]

  • 16. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
    Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, Malafaia O, Fernandez A, Choe KA, Carides A, Satishchandran V, Teppler H, Protocol 017 Study Group.
    Ann Surg; 2003 Feb; 237(2):235-45. PubMed ID: 12560782
    [Abstract] [Full Text] [Related]

  • 17. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
    Hou F, Li J, Gao L, Chen Y.
    Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
    [Abstract] [Full Text] [Related]

  • 18. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
    DiNubile MJ, Chow JW, Satishchandran V, Polis A, Motyl MR, Abramson MA, Teppler H.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3217-21. PubMed ID: 16048928
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
    Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD.
    Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828
    [Abstract] [Full Text] [Related]

  • 20. Concentrations of piperacillin-tazobactam in human jaw and hip bone.
    Al-Nawas B, Kinzig-Schippers M, Soergel F, Shah PM.
    J Craniomaxillofac Surg; 2008 Dec; 36(8):468-72. PubMed ID: 18783957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.